Dibucaine
Anesthetics, Local
Prilocaine
Procaine
Lidocaine
Levallorphan
Rana temporaria
para-Aminobenzoates
4-Aminobenzoic Acid
Amphibian Venoms
Phlebotomy
Anesthesia, Local
Iophendylate
Ointments
Calcium
Caffeine
Effects of tetracaine on sarcoplasmic calcium release in mammalian skeletal muscle fibres. (1/340)
1. Single muscle fibres were dissociated enzymatically from the extensor digitorum communis muscle of rats. The fibres were mounted into a double Vaseline gap experimental chamber and the events in excitation-contraction coupling were studied under voltage clamp conditions in the presence and absence of the local anaesthetic tetracaine. 2. Changes in intracellular calcium concentration ([Ca2+]i) were monitored using the calcium sensitive dyes antipyrylazo III and fura-2 and the rate of calcium release (Rrel) from the sarcoplasmic reticulum (SR) was calculated. Tetracaine decreased the maximal attained [Ca2+]i and suppressed, in a dose-dependent manner, both the early peak and the steady level of Rrel in the voltage range examined. 3. The concentration dependence of the effects on the two kinetic components of Rrel were almost identical with a half-effective concentration (K50) of 70 and 71 microM and a Hill coefficient (nH) of 2.7 and 2.3 for the peak and the steady level, respectively. Furthermore, the drug did not alter the peak to steady level ratio up to a concentration (50 microM) that caused a 35 +/- 5 % reduction in calcium release. Higher concentrations did suppress the ratio but the degree of suppression was voltage independent. 4. Tetracaine (50 microM) neither influenced the total available intramembrane charge nor altered its membrane potential dependence. It shifted the transfer function, the normalized SR permeability versus normalized charge to the right, indicating that similar charge transfer caused a smaller increase in SR permeability. 5. To explore the site of action of tetracaine further the ryanodine receptor (RyR) calcium release channel of the SR was purified and reconstituted into planar lipid bilayers. The reconstituted channel had a conductance of 511 +/- 14 pS (n = 8) in symmetric 250 mM KCl that was not affected by tetracaine. Tetracaine decreased the open probability of the channel in a concentration-dependent manner with K50 = 68 microM and nH = 1.5. 6. These experiments show that tetracaine suppresses SR calcium release in enzymatic isolated mammalian skeletal muscle fibres. This effect is due, presumably, to the decreased open probability of the RyR in the presence of the drug. Since both the inactivating peak and the steady level of Rrel were equally affected by tetracaine, our observations suggest that there is a tight coupling between these kinetic components of SR calcium release in mammalian skeletal muscle. (+info)Interaction of bupivacaine and tetracaine with the sarcoplasmic reticulum Ca2+ release channel of skeletal and cardiac muscles. (2/340)
BACKGROUND: Although various local anesthetics can cause histologic damage to skeletal muscle when injected intramuscularly, bupivacaine appears to have an exceptionally high rate of myotoxicity. Research has suggested that an effect of bupivacaine on sarcoplasmic reticulum Ca2+ release is involved in its myotoxicity, but direct evidence is lacking. Furthermore, it is not known whether the toxicity depends on the unique chemical characteristics of bupivacaine and whether the toxicity is found only in skeletal muscle. METHODS: The authors studied the effects of bupivacaine and the similarly lipid-soluble local anesthetic, tetracaine, on the Ca2+ release channel-ryanodine receptor of sarcoplasmic reticulum in swine skeletal and cardiac muscle. [3H]Ryanodine binding was used to measure the activity of the Ca2+ release channel-ryanodine receptors in microsomes of both muscles. RESULTS: Bupivacaine enhanced (by two times at 5 mM) and inhibited (66% inhibition at 10 mM) [3H]ryanodine binding to skeletal muscle microsomes. In contrast, only inhibitory effects were observed with cardiac microsomes (about 3 mM for half-maximal inhibition). Tetracaine, which inhibits [3H]ryanodine binding to skeletal muscle microsomes, also inhibited [3H]ryanodine binding to cardiac muscle microsomes (half-maximal inhibition at 99 microM). CONCLUSIONS: Bupivacaine's ability to enhance Ca2+ release channel-ryanodine receptor activity of skeletal muscle sarcoplasmic reticulum most likely contributes to the myotoxicity of this local anesthetic. Thus, the pronounced myotoxicity of bupivacaine may be the result of this specific effect on Ca2+ release channel-ryanodine receptor superimposed on a nonspecific action on lipid bilayers to increase the Ca2+ permeability of sarcoplasmic reticulum membranes, an effect shared by all local anesthetics. The specific action of tetracaine to inhibit Ca2+ release channel-ryanodine receptor activity may in part counterbalance the nonspecific action, resulting in moderate myotoxicity. (+info)Topical anaesthesia of intact skin: liposome-encapsulated tetracaine vs EMLA. (3/340)
In this randomized, double-blind study, we have compared the ability of 5% liposome-encapsulated tetracaine (amethocaine) (LET) vs 5% eutectic mixture of local anaesthetics (EMLA) to produce local anaesthesia of intact skin in 40 healthy volunteers. Volunteers had both preparations applied to their forearms under an occlusive dressing for 1 h. Superficial anaesthesia was measured by a total of nine 1-mm pinpricks on each arm. Deeper anaesthesia was assessed by single insertion of a sterile 22-gauge needle to a depth of 3 mm and pain was reported on a visual analogue scale (VAS). If the volunteer perceived greater than four of the 1-mm pinpricks, the 3-mm insertion was not performed. Results showed that the number of pinpricks perceived was significantly less (P < 0.01) for LET (median 1.0; range 0-9) vs EMLA (1.5; 0-9). In volunteers who had deeper anaesthesia assessed, there was no significant difference (P = 0.065) in VAS scores for LET (mean 1.5 (SD 1.4); n = 34) vs EMLA (2.4 (2.1); n = 28). Overall anaesthetic effect, as ranked by all of the subjects, was significantly better for LET compared with EMLA (P = 0.024). We have demonstrated that when applied in equal volumes, 5% LET produced better superficial local anaesthesia than EMLA. (+info)Isolation and characterization of the yeast las21 mutants, which are sensitive to a local anestheticum, tetracaine. (4/340)
We isolated and characterized yeast mutants whose growth is sensitive to a local anestheticum tetracaine and, at the same time, temperature sensitive. These mutants were collectively called las mutants (local anestheticum sensitive). The las21 mutants were analyzed in this study. The wild type LAS21 gene was cloned by exploiting temperature sensitivity of the las21 mutants and we found that LAS21 encodes ORF YJL062w which has not been analyzed before. Las21p is putative membrane protein belonging to the major facilitator super family containing plural membrane spanning domains. Complete elimination of the LAS21 ORF did not kill the cells but made their growth temperature sensitive. Interestingly, the complete loss of the LAS21 gene canceled the sensitivity to tetracaine. The ability of the las21 mutants to grow at a higher temperature was recovered in the various media containing an osmotic stabilizer or salts. Furthermore, temperature sensitivity of the las21 mutants was partially suppressed by introduction of PKC1, encoding protein kinase C, on a high copy vector. We found some genetic interactions between LAS21 and Ras/cAMP cascade genes. These results suggest that LAS21 defines unknown pathway regulating the stress response of yeast. (+info)Photoaffinity labeling the torpedo nicotinic acetylcholine receptor with [(3)H]tetracaine, a nondesensitizing noncompetitive antagonist. (5/340)
Tetracaine (N,N-dimethylaminoethyl-4-butylaminobenzoate) and related N,N-dialkylaminoethyl substituted benzoic acid esters have been used to characterize the high-affinity binding site for aromatic amine noncompetitive antagonists in the Torpedo nicotinic acetylcholine receptor (nAChR). [(3)H]Tetracaine binds at equilibrium to a single site with a K(eq) value of 0.5 microM in the absence of agonist or presence of alpha-bungarotoxin and with a K(eq) value of 30 microM in the presence of agonist (i.e., for nAChR in the desensitized state). Preferential binding to nAChR in the absence of agonist is also seen for N,N-DEAE and N,N-diethylaminopropyl esters, both binding with 10-fold higher affinity in the absence of agonist than in the presence, and for the 4-ethoxybenzoic acid ester of N, N-diethylaminoethanol, but not for the 4-amino benzoate ester (procaine). Irradiation at 302 nm of nAChR-rich membranes equilibrated with [(3)H]tetracaine resulted in covalent incorporation with similar efficiency into nAChR alpha, beta, gamma, and delta subunits. The pharmacological specificity of nAChR subunit photolabeling as well as its dependence on [(3)H]tetracaine concentration establish that the observed photolabeling is at the high-affinity [(3)H]tetracaine-binding site. Within alpha subunit, >/=95% of specific photolabeling was contained within a 20-kilodalton proteolytic fragment beginning at Ser(173) that contains the M1 to M3 hydrophobic segments. With all four subunits contributing to [(3)H]tetracaine site, the site in the closed channel state of the nAChR is most likely within the central ion channel domain. (+info)Identification of amino acids of the torpedo nicotinic acetylcholine receptor contributing to the binding site for the noncompetitive antagonist [(3)H]tetracaine. (6/340)
[(3)H]Tetracaine is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor (nAChR) that binds with high affinity in the absence of cholinergic agonist (K(eq) = 0.5 microM) and weakly (K(eq) = 30 microM) in the presence of agonist (i.e., to nAChR in the desensitized state). In the absence of agonist, irradiation at 302 nm of nAChR-rich membranes equilibrated with [(3)H]tetracaine results in specific photoincorporation of [(3)H]tetracaine into each nAChR subunit. In this report, we identify the amino acids of each nAChR subunit specifically photolabeled by [(3)H]tetracaine that contribute to the high-affinity binding site. Subunits isolated from nAChR-rich membranes photolabeled with [(3)H]tetracaine were subjected to enzymatic digestion, and peptides containing (3)H were purified by SDS-polyacrylamide gel electrophoresis followed by reversed phase HPLC. N-terminal sequence analysis of the isolated peptides demonstrated that [(3)H]tetracaine specifically labeled two sets of homologous hydrophobic residues (alphaLeu(251), betaLeu(257), gammaLeu(260), and deltaLeu(265); alphaVal(255) and deltaVal(269)) as well as alphaIle(247) and deltaAla(268) within the M2 hydrophobic segments of each subunit. The labeling of these residues establishes that the high-affinity [(3)H]tetracaine-binding site is located within the lumen of the closed ion channel and provides a definition of the surface of the M2 helices facing the channel lumen. (+info)Tetracaine can inhibit contractions initiated by a voltage-sensitive release mechanism in guinea-pig ventricular myocytes. (7/340)
1. Effects of tetracaine on membrane currents and cell shortening were measured with high resistance electrodes, single-electrode voltage clamp (switch clamp) and a video edge detector at 37 C in cardiac ventricular myocytes. 2. Sequential voltage steps from -65 mV to -40 and 0 mV were used to activate two mechanisms of excitation-contraction (EC) coupling separately. The step to -40 mV activated the voltage-sensitive release mechanism (VSRM); the step to 0 mV1 activated Ca2+-induced Ca2+ release (CICR) coupled to inward Ca2+ current (IL). 3. Exposure to 100-300 microM tetracaine inhibited VSRM contractions but not CICR contractions. Inhibition of VSRM contractions was independent of INa blockade. In contrast, 100 microM Cd2+ blocked IL and CICR contractions, but not VSRM contractions. Simultaneous application of both agents blocked both mechanisms of EC coupling. 4. Contraction-voltage relationships were sigmoidal when the VSRM was available. However, when the VSRM was inhibited with 100-300 microM tetracaine, contraction-voltage relationships became bell-shaped. The tetracaine-insensitive contractions were abolished by 0.1 microM ryanodine, indicating that they were dependent on release of SR Ca2+. 5. At a higher concentration (1 mM) tetracaine also inhibited IL and contractions triggered by IL; however, the time course of effects on IL and associated contractions were different than for VSRM contractions. 6. With continuous application of tetracaine, the VSRM remained inhibited although SR Ca2+ stores increased 4-fold as assessed with caffeine. CICR contractions were not inhibited and maximum amplitude of contraction was not reduced. 7. Rapid application of tetracaine just before and during test steps also inhibited VSRM contractions, but without significantly affecting sarcoplasmic reticulum (SR) Ca2+ stores or CICR contractions. Maximum amplitude of contraction was reduced. 8. Rapid application of tetracaine (100-300 microM) allows preferential inhibition of the VSRM and provides a pharmacological method to assess the contribution of the VSRM to EC coupling. (+info)Tetracaine gel vs EMLA cream for percutaneous anaesthesia in children. (8/340)
We have evaluated the anaesthetic effect of tetracaine gel 1 g, applied for 45 min, compared with EMLA cream 2 g, applied for 60 min, in a randomized, double-blind study in 60 children aged 3-15 yr. Venous cannulation was performed 15 min after removal of the EMLA cream (n = 20) and tetracaine gel (n = 20). Cannulation was performed up to 215 min after removal of the tetracaine gel in another 20 patients. Significantly lower pain scores were recorded by the children treated with tetracaine gel compared with EMLA cream (P < 0.02). Forty to 45% of children in the tetracaine groups reported no pain compared with only 10% in the EMLA group. Only minor adverse effects were observed. We conclude that tetracaine gel provided effective, rapid, long-lasting and safe local anaesthesia, and was significantly better than EMLA cream in reducing pain during venous cannulation in children using the recommended application periods for both formulations. (+info)Tetracaine is a local anesthetic commonly used for surface anesthesia of the eye, ear, and mucous membranes. It functions by blocking the nerve impulses in the area where it's applied, thereby numbing the area and relieving pain. It's available in various forms such as solutions, ointments, and sprays. Please note that all medical procedures and treatments should be conducted under the supervision of a healthcare professional.
Dibucaine is a local anesthetic drug that is used to numb the skin or mucous membranes before medical procedures. It works by blocking the nerve signals in the area where it is applied, preventing the sensation of pain. Dibucaine is available as a topical cream, ointment, or gel, and it may also be used as an ingredient in lozenges or throat sprays to relieve sore throats.
Dibucaine has been largely replaced by other local anesthetics due to its potential for causing allergic reactions and other side effects. It is important to follow your healthcare provider's instructions carefully when using dibucaine, and to inform them of any medical conditions or medications you are taking that may interact with the drug.
Local anesthetics are a type of medication that is used to block the sensation of pain in a specific area of the body. They work by temporarily numbing the nerves in that area, preventing them from transmitting pain signals to the brain. Local anesthetics can be administered through various routes, including topical application (such as creams or gels), injection (such as into the skin or tissues), or regional nerve blocks (such as epidural or spinal anesthesia).
Some common examples of local anesthetics include lidocaine, prilocaine, bupivacaine, and ropivacaine. These medications can be used for a variety of medical procedures, ranging from minor surgeries (such as dental work or skin biopsies) to more major surgeries (such as joint replacements or hernia repairs).
Local anesthetics are generally considered safe when used appropriately, but they can have side effects and potential complications. These may include allergic reactions, toxicity (if too much is administered), and nerve damage (if the medication is injected into a nerve). It's important to follow your healthcare provider's instructions carefully when using local anesthetics, and to report any unusual symptoms or side effects promptly.
Prilocaine is an amide local anesthetic that is often used in topical, injectable, and regional anesthesia. It is commonly combined with lidocaine to reduce the risk of methhemoglobinemia, a rare but potentially serious side effect that can occur with prilocaine use.
Prilocaine works by blocking sodium channels in nerve cell membranes, which prevents the transmission of nerve impulses and results in local anesthesia. It has a rapid onset of action and a relatively short duration of effect.
In addition to its use as a local anesthetic, prilocaine is also used in some dental procedures and for the treatment of premature ejaculation. As with any medication, prilocaine can have side effects, including allergic reactions, numbness, tingling, and pain at the injection site. It should be used with caution in patients with certain medical conditions, such as heart disease, liver or kidney dysfunction, and in pregnant or breastfeeding women.
Procaine is a local anesthetic drug that is used to reduce the feeling of pain in a specific area of the body. It works by blocking the nerves from transmitting painful sensations to the brain. Procaine is often used during minor surgical procedures, dental work, or when a patient needs to have a wound cleaned or stitched up. It can also be used as a diagnostic tool to help determine the source of pain.
Procaine is administered via injection directly into the area that requires anesthesia. The effects of procaine are relatively short-lived, typically lasting between 30 minutes and two hours, depending on the dose and the individual's metabolism. Procaine may also cause a brief period of heightened sensory perception or euphoria following injection, known as "procaine rush."
It is important to note that procaine should only be administered by trained medical professionals, as improper use can lead to serious complications such as allergic reactions, respiratory depression, and even death.
Lidocaine is a type of local anesthetic that numbs painful areas and is used to prevent pain during certain medical procedures. It works by blocking the nerves that transmit pain signals to the brain. In addition to its use as an anesthetic, lidocaine can also be used to treat irregular heart rates and relieve itching caused by allergic reactions or skin conditions such as eczema.
Lidocaine is available in various forms, including creams, gels, ointments, sprays, solutions, and injectable preparations. It can be applied directly to the skin or mucous membranes, or it can be administered by injection into a muscle or vein. The specific dosage and method of administration will depend on the reason for its use and the individual patient's medical history and current health status.
Like all medications, lidocaine can have side effects, including allergic reactions, numbness that lasts too long, and in rare cases, heart problems or seizures. It is important to follow the instructions of a healthcare provider carefully when using lidocaine to minimize the risk of adverse effects.
Levallorphan is a opioid antagonist and agonist, often used as an analgesic (pain reliever) and antitussive (cough suppressant). It works by binding to the opioid receptors in the brain, blocking the effects of certain opioid agonists such as morphine while also acting as a weak agonist itself. This means that it can both block the pain-relieving effects and produce some of the unwanted side effects of opioids, such as respiratory depression. It is used in clinical settings to reverse or reduce the effects of opioid overdose, and also for the treatment of severe cough.
It's important to note that Levallorphan has a complex pharmacology and its use should be restricted to medical professionals due to its potential for abuse and dependence.
"Rana temporaria" is the scientific name for the common European frog, also known as the grass frog. It's a widespread species found throughout Europe and into western Asia. These frogs are typically brown or green in color with darker spots, and they can change their color to some extent based on their environment. They are semi-aquatic, spending time both in water and on land, and are known for their distinctive mating call.
However, if you're looking for a medical definition, there isn't one for "Rana temporaria." The term is strictly biological and refers to this specific species of frog.
Para-aminobenzoates are a group of compounds that contain a para-aminobenzoic acid (PABA) molecule. PABA is an organic compound that is related to benzoic acid and aminobenzoic acid. It is not an essential nutrient for humans, but it does play a role in the metabolism of certain bacteria.
Para-aminobenzoates are often used as ingredients in sunscreens because PABA absorbs ultraviolet (UV) light and can help protect the skin from sun damage. However, para-aminobenzoates can cause skin irritation and allergic reactions in some people, so they have largely been replaced by other UV-absorbing compounds in modern sunscreens.
In addition to their use in sunscreens, para-aminobenzoates are also used in the treatment of various medical conditions. For example, they may be used as a topical agent to treat fungal infections or as a systemic therapy to treat rheumatoid arthritis and other inflammatory conditions.
It is important to note that para-aminobenzoates should not be confused with paracetamol (also known as acetaminophen), which is a commonly used pain reliever and fever reducer. While both compounds contain the word "para," they are chemically distinct and have different uses in medicine.
4-Aminobenzoic acid, also known as PABA or para-aminobenzoic acid, is an organic compound that is a type of aromatic amino carboxylic acid. It is a white, crystalline powder that is slightly soluble in water and more soluble in alcohol.
4-Aminobenzoic acid is not an essential amino acid for humans, but it is a component of the vitamin folic acid and is found in various foods such as meat, whole grains, and molasses. It has been used as a topical sunscreen due to its ability to absorb ultraviolet (UV) radiation, although its effectiveness as a sunscreen ingredient has been called into question in recent years.
In addition to its use in sunscreens, 4-aminobenzoic acid has been studied for its potential health benefits, including its possible role in protecting against UV-induced skin damage and its potential anti-inflammatory and analgesic effects. However, more research is needed to confirm these potential benefits and to determine the safety and effectiveness of 4-aminobenzoic acid as a dietary supplement or topical treatment.
Spinal anesthesia is a type of regional anesthesia that involves injecting local anesthetic medication into the cerebrospinal fluid in the subarachnoid space, which is the space surrounding the spinal cord. This procedure is typically performed by introducing a needle into the lower back, between the vertebrae, to reach the subarachnoid space.
Once the local anesthetic is introduced into this space, it spreads to block nerve impulses from the corresponding levels of the spine, resulting in numbness and loss of sensation in specific areas of the body below the injection site. The extent and level of anesthesia depend on the amount and type of medication used, as well as the patient's individual response.
Spinal anesthesia is often used for surgeries involving the lower abdomen, pelvis, or lower extremities, such as cesarean sections, hernia repairs, hip replacements, and knee arthroscopies. It can also be utilized for procedures like epidural steroid injections to manage chronic pain conditions affecting the spine and lower limbs.
While spinal anesthesia provides effective pain relief during and after surgery, it may cause side effects such as low blood pressure, headache, or difficulty urinating. These potential complications should be discussed with the healthcare provider before deciding on this type of anesthesia.
Amphibian venoms are toxic secretions produced by certain species of amphibians, such as frogs, toads, and salamanders. These secretions are often produced by specialized glands in the skin and can contain a variety of bioactive compounds, including alkaloids, steroids, peptides, and proteins. Some amphibian venoms can cause painful burns or irritation upon contact with the skin, while others can be deadly if ingested or introduced into the bloodstream through wounds or mucous membranes.
The study of amphibian venoms has gained increasing attention in recent years due to their potential as sources of novel bioactive compounds with therapeutic applications. For example, some peptides found in amphibian venoms have been shown to have potent analgesic, anti-inflammatory, and antimicrobial properties, making them promising candidates for the development of new drugs.
It is important to note that not all amphibians produce venom, and even those that do may use their toxic secretions primarily for defense against predators rather than for hunting prey. Additionally, while some amphibian venoms can be dangerous or even lethal to humans, most cases of envenomation occur in the context of intentional handling or accidental contact with these animals in their natural habitats.
Phlebotomy is a medical term that refers to the process of making an incision in a vein, usually in the arm, in order to draw blood. It is also commonly known as venipuncture. This procedure is performed by healthcare professionals for various purposes such as diagnostic testing, blood donation, or therapeutic treatments like phlebotomy for patients with hemochromatosis (a condition where the body absorbs too much iron from food).
The person who performs this procedure is called a phlebotomist. They must be trained in the proper techniques to ensure that the process is safe and relatively pain-free for the patient, and that the blood sample is suitable for laboratory testing.
Local anesthesia is a type of anesthesia that numbs a specific area of the body, blocking pain signals from that particular region while allowing the person to remain conscious and alert. It is typically achieved through the injection or application of a local anesthetic drug, which works by temporarily inhibiting the function of nerve fibers carrying pain sensations. Common examples of local anesthetics include lidocaine, prilocaine, and bupivacaine.
Local anesthesia is commonly used for minor surgical procedures, dental work, or other medical interventions where only a small area needs to be numbed. It can also be employed as part of a combined anesthetic technique, such as in conjunction with sedation or regional anesthesia, to provide additional pain relief and increase patient comfort during more extensive surgeries.
The duration of local anesthesia varies depending on the type and dosage of the anesthetic agent used; some last for just a few hours, while others may provide numbness for up to several days. Overall, local anesthesia is considered a safe and effective method for managing pain during various medical procedures.
Iophendylate is not typically referred to as a medical definition, but it is the chemical name for a contrast agent that is used in radiology procedures. It is a type of oil-based contrast medium that is injected into the cerebrospinal fluid (CSF) during myelography, which is an imaging test used to visualize the spinal cord and surrounding structures.
Iophendylate, also known as Pantopaque, is a heavy oily substance that outlines the spinal canal and nerve roots on X-ray images, allowing radiologists to diagnose various conditions such as herniated discs, spinal stenosis, or tumors. However, due to the risks associated with its use, including chemical meningitis and potential neurological complications, it has largely been replaced by water-soluble contrast agents in current clinical practice.
An ointment is a semi-solid preparation, typically composed of a mixture of medicinal substance with a base, which is usually greasy or oily. The purpose of the base is to act as a vehicle for the active ingredient and allow it to be applied smoothly and evenly to the skin or mucous membranes.
Ointments are commonly used in dermatology to treat various skin conditions such as eczema, psoriasis, rashes, burns, and wounds. They can also be used to deliver medication for localized pain relief, muscle relaxation, and anti-inflammatory or antibiotic effects.
The base of an ointment may consist of various ingredients, including petrolatum, lanolin, mineral oil, beeswax, or a combination of these. The choice of the base depends on the desired properties such as consistency, spreadability, and stability, as well as the intended route of administration and the specific therapeutic goals.
Calcium is an essential mineral that is vital for various physiological processes in the human body. The medical definition of calcium is as follows:
Calcium (Ca2+) is a crucial cation and the most abundant mineral in the human body, with approximately 99% of it found in bones and teeth. It plays a vital role in maintaining structural integrity, nerve impulse transmission, muscle contraction, hormonal secretion, blood coagulation, and enzyme activation.
Calcium homeostasis is tightly regulated through the interplay of several hormones, including parathyroid hormone (PTH), calcitonin, and vitamin D. Dietary calcium intake, absorption, and excretion are also critical factors in maintaining optimal calcium levels in the body.
Hypocalcemia refers to low serum calcium levels, while hypercalcemia indicates high serum calcium levels. Both conditions can have detrimental effects on various organ systems and require medical intervention to correct.
Caffeine is a central nervous system stimulant that occurs naturally in the leaves, seeds, or fruits of some plants. It can also be produced artificially and added to various products, such as food, drinks, and medications. Caffeine has a number of effects on the body, including increasing alertness, improving mood, and boosting energy levels.
In small doses, caffeine is generally considered safe for most people. However, consuming large amounts of caffeine can lead to negative side effects, such as restlessness, insomnia, rapid heart rate, and increased blood pressure. It is also possible to become dependent on caffeine, and withdrawal symptoms can occur if consumption is suddenly stopped.
Caffeine is found in a variety of products, including coffee, tea, chocolate, energy drinks, and some medications. The amount of caffeine in these products can vary widely, so it is important to pay attention to serving sizes and labels to avoid consuming too much.
Tetracaine - Wikipedia
Tetracaine
Chloramphenicol / Prednisolone / Tetracaine / Squalane for dogs: Uses, Dosage & Side Effects
Lidocaine%3B+Tetracaine - 505(b)(2) development and clinical trial profile - locations, diseases, companies
Dibucaine and Tetracaine Inhibit the Activation of Mitogen-activated Protein Kinase Mediated by L-type Calcium Channels in PC12...
Tetracaine - Core EM
Tetracaine - LGM Pharma
Tetracaine - Active ingredient - Grovet.com
Tetracaine Hydrochloride in Obstetrics | InsightIgnite 
Médicament vitamine c chlorhexidine tetracaine
Tetracaine CAS 94-24-6
Tetracaine Prescribing Information - TheMediTary.Com
Benzocaine Tetracaine Lidocaine Hydrochloride For Local Anesthetic
Tetracaine Lollipops for Pediatric Tonsillectomies & Oral Procedures
Ametop (Tetracaine 4%w/w) Gel 1.5G - Biopharmtech
Tetracaine gel 4% dosage, indications, side effects, and more
Buyer Tetracaine hcl powder cas 136-47-0 with best quality
CAS 136-47-0 Hydrochloride HCl Lidocaine Procaine Tetracaine - China Tetracaine and Tetracaine HCl
Compounded Tetracaine Archives - Morgan Compounding Pharmacy - Alpharetta, Georgia - Fill Rx Prescription for Adults, Children,...
St. Renatus LLC Company Information - Drugs.com